Lorus Wins Patent for New Leukemia Drug
Lorus Wins Patent for New Leukemia Drug
redOrbit
Posted on: Wednesday, 30 July 2008
Lorus Therapeutics has received a new patent from the US Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.
The patent protects methods of treating leukemia with LOR-2040, both alone and in combination with chemotherapy drugs. The patent also covers methods of treating specific solid cancers with LOR-2040, including colon, lung, breast, and bladder cancers. LOR-2040 composition as well as its design and use as a unique anticancer drug is currently protected in the US under a separate patent issued in 1999.
The company announced that in a recently completed proof-of-concept clinical trial, patients with relapsed or refractory acute myeloid leukemia (AML) showed a 35% complete response rate, accumulation of LOR-2040 in tumor cells, and down regulation of its biochemical target following treatment with LOR-2040 in combination with HiDAC.
Aiping Young, Lorus's president and CEO, said: "This newly issued US patent adds additional strength to our global IP position for this drug, and supports the potential development in other cancers in a major market."
Source: Datamonitor
© 2002-2009 redOrbit.com
Votes:32
Comments: 0